|Day Low/High||0.61 / 0.67|
|52 Wk Low/High||0.50 / 3.48|
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.
Risky late-game call puts Poniard in a deep financial hole.
Is it the drug or the gel that worked best in a phase II study?
The fall in Cardium shares might be related, at least partially, to what looks like so-so results from a phase IIb study announced on Oct. 14.
Cardium Therapeutics fell sharply on heavy volume after it announced a $6 million registered direct offering.